| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.0031 | 1 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.0038 | 1 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.0024 | 1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0017 | 1 |